24,400 Shares in Emergent Biosolutions Inc. $EBS Purchased by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. acquired a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,400 shares of the biopharmaceutical company’s stock, valued at approximately $156,000.

Other hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC raised its holdings in Emergent Biosolutions by 313.5% in the first quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock worth $4,048,000 after buying an additional 631,794 shares during the last quarter. Prescott Group Capital Management L.L.C. raised its holdings in shares of Emergent Biosolutions by 198.9% during the first quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock valued at $3,050,000 after purchasing an additional 417,671 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after purchasing an additional 121,583 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Emergent Biosolutions by 22.4% during the first quarter. New York State Common Retirement Fund now owns 375,034 shares of the biopharmaceutical company’s stock valued at $1,823,000 after purchasing an additional 68,748 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new position in shares of Emergent Biosolutions during the second quarter valued at approximately $227,000. Institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Stock Performance

Shares of NYSE EBS opened at $9.77 on Monday. The firm has a 50 day moving average of $8.78 and a 200 day moving average of $7.18. The company has a current ratio of 5.66, a quick ratio of 3.00 and a debt-to-equity ratio of 1.25. The firm has a market capitalization of $520.96 million, a price-to-earnings ratio of 3.99 and a beta of 2.04. Emergent Biosolutions Inc. has a 12-month low of $4.02 and a 12-month high of $12.73.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. The business had revenue of $222.50 million for the quarter. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. Emergent Biosolutions has set its FY 2023 guidance at EPS. On average, research analysts anticipate that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Kathryn C. Zoon sold 7,086 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $8.87, for a total value of $62,852.82. Following the transaction, the director owned 71,799 shares of the company’s stock, valued at approximately $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Coleen Glessner sold 30,608 shares of the company’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total transaction of $306,080.00. Following the transaction, the executive vice president owned 144,319 shares of the company’s stock, valued at approximately $1,443,190. This represents a 17.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 45,538 shares of company stock worth $436,783 over the last three months. 3.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EBS. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Emergent Biosolutions in a report on Friday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.50.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.